The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Clinical trial enrollment has long been a bottleneck in drug development
Subscribe To Our Newsletter & Stay Updated
